Aprea Therapeutics Files 2024 10-K
Ticker: APRE · Form: 10-K · Filed: Mar 25, 2025 · CIK: 1781983
| Field | Detail |
|---|---|
| Company | Aprea Therapeutics, Inc. (APRE) |
| Form Type | 10-K |
| Filed Date | Mar 25, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, pharmaceuticals, financials
TL;DR
Aprea Therapeutics filed its 2024 10-K, detailing financials and operations for the year ending Dec 31, 2024.
AI Summary
Aprea Therapeutics, Inc. filed its 2024 10-K on March 25, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The company, focused on pharmaceutical preparations, is incorporated in Delaware and headquartered in Doylestown, PA. Key financial details and operational highlights for 2024 are presented in this annual report.
Why It Matters
This filing provides investors and stakeholders with a comprehensive overview of Aprea Therapeutics' financial health, strategic direction, and risk factors for the past fiscal year.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Aprea Therapeutics faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 5509921 — Total Assets (Reported for the fiscal year ending December 31, 2024.)
- 3617607 — Total Liabilities (Reported for the fiscal year ending December 31, 2024.)
- 3736673 — Total Equity (Reported for the fiscal year ending December 31, 2024.)
- 5481055 — Total Revenue (Reported for the fiscal year ending December 31, 2024.)
Key Players & Entities
- Aprea Therapeutics, Inc. (company) — Filer of the 10-K
- 2024-12-31 (date) — Fiscal year end
- 2025-03-25 (date) — Filing date
- Doylestown, PA (location) — Company headquarters
- 2834 (industry_code) — Standard Industrial Classification for Pharmaceutical Preparations
FAQ
What was Aprea Therapeutics' net income or loss for the fiscal year ended December 31, 2024?
The provided excerpt does not explicitly state the net income or loss for the fiscal year ended December 31, 2024. Further details within the full 10-K filing would be required to determine this.
What is the total number of shares outstanding as of December 31, 2024?
The filing indicates '56227' shares for 'us-gaap:CommonStockMember' and '56227' for 'apre:ConvertiblePreferredStockSeriesaMember' in relation to the fiscal year end, but the exact total outstanding shares requires a more detailed review of the full report.
Did Aprea Therapeutics engage in any at-market offerings during 2024?
Yes, the filing references 'apre:AtMarketOfferingMember' for the period of '2024-01-01' to '2024-12-31', indicating at-market offerings occurred.
What is the company's primary business activity?
Aprea Therapeutics, Inc. is classified under Standard Industrial Classification code 2834, which corresponds to Pharmaceutical Preparations.
When was Aprea Therapeutics incorporated and in which state?
Aprea Therapeutics, Inc. was incorporated in Delaware (DE).
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 25, 2025 regarding Aprea Therapeutics, Inc. (APRE).